Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Shares Outstanding (Diluted Average) (2019 - 2025)

Autolus Therapeutics (AUTL) has disclosed Shares Outstanding (Diluted Average) for 7 consecutive years, with $266.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Diluted Average) rose 5.83% year-over-year to $266.1 million, compared with a TTM value of $266.1 million through Sep 2025, up 5.83%, and an annual FY2024 reading of $255.2 million, up 46.69% over the prior year.
  • Shares Outstanding (Diluted Average) was $266.1 million for Q3 2025 at Autolus Therapeutics, roughly flat from $266.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $266.1 million in Q2 2025 and bottomed at $72.1 million in Q4 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $183.1 million, with a median of $173.9 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) surged 91.2% in 2023, then rose 0.04% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $72.1 million in 2021, then surged by 31.78% to $95.0 million in 2022, then surged by 83.11% to $173.9 million in 2023, then soared by 46.69% to $255.2 million in 2024, then increased by 4.3% to $266.1 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for AUTL at $266.1 million in Q3 2025, $266.1 million in Q2 2025, and $266.1 million in Q1 2025.